Lumos Pharma Inc (LUMO)
4.30
-0.03
(-0.69%)
USD |
NASDAQ |
Nov 22, 11:09
Lumos Pharma Enterprise Value: 23.93M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 23.93M |
| November 20, 2024 | 23.84M |
| November 19, 2024 | 23.93M |
| November 18, 2024 | 23.84M |
| November 15, 2024 | 23.93M |
| November 14, 2024 | 23.93M |
| November 13, 2024 | 23.67M |
| November 12, 2024 | 24.19M |
| November 11, 2024 | 24.28M |
| November 08, 2024 | 24.18M |
| November 07, 2024 | 23.89M |
| November 06, 2024 | 23.76M |
| November 05, 2024 | 24.45M |
| November 04, 2024 | 24.66M |
| November 01, 2024 | 24.27M |
| October 31, 2024 | 24.88M |
| October 30, 2024 | 24.01M |
| October 29, 2024 | 24.27M |
| October 28, 2024 | 24.97M |
| October 25, 2024 | 24.53M |
| October 24, 2024 | 24.10M |
| October 23, 2024 | 24.19M |
| October 22, 2024 | 20.64M |
| October 21, 2024 | 18.74M |
| October 18, 2024 | 21.25M |
| Date | Value |
|---|---|
| October 17, 2024 | 19.17M |
| October 16, 2024 | 21.16M |
| October 15, 2024 | 20.99M |
| October 14, 2024 | 20.21M |
| October 11, 2024 | 19.26M |
| October 10, 2024 | 19.80M |
| October 09, 2024 | 18.65M |
| October 08, 2024 | 19.78M |
| October 07, 2024 | 19.86M |
| October 04, 2024 | 17.10M |
| October 03, 2024 | 18.05M |
| October 02, 2024 | 18.22M |
| October 01, 2024 | 17.53M |
| September 30, 2024 | 19.95M |
| September 27, 2024 | 15.21M |
| September 26, 2024 | 14.40M |
| September 25, 2024 | 16.10M |
| September 24, 2024 | 15.05M |
| September 23, 2024 | 13.75M |
| September 20, 2024 | 15.13M |
| September 19, 2024 | 15.05M |
| September 18, 2024 | 13.26M |
| September 17, 2024 | 14.72M |
| September 16, 2024 | 14.64M |
| September 13, 2024 | 15.13M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-48.12M
Minimum
Dec 12 2022
197.90M
Maximum
Dec 31 2020
-3.308M
Average
-12.26M
Median
Jan 18 2024
Enterprise Value Benchmarks
| Boston Scientific Corp | 143.48B |
| Calidi Biotherapeutics Inc | 41.71M |
| NovaBay Pharmaceuticals Inc | 2.798M |
| Palatin Technologies Inc | 15.96M |
| iBio Inc | 12.31M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.467M |
| Revenue (Quarterly) | 0.726M |
| Total Expenses (Quarterly) | 8.366M |
| EPS Diluted (Quarterly) | -0.90 |
| Profit Margin (Quarterly) | -1.03K% |
| Earnings Yield | -99.77% |
| Normalized Earnings Yield | -99.77 |